Certara, INC 8-K filings

Certara, Inc. clarifies a misstatement regarding the 2025 adjusted EBITDA of its divested Regulatory and Medical Writing business, confirming no impact on prior financial results or future outlook.

Certara announced its second quarter 2026 financial results, reporting modest revenue growth, a net loss, and a decrease in Adjusted EBITDA, while reaffirming its full-year revenue guidance and authorizing an additional $50 million share repurchase program.

Certara, Inc. reports the departure of its President and Chief Commercial Officer, Leif E. Pedersen, effective August 1, 2026, with a transition plan in place.

Certara announced its first quarter 2026 financial results, reporting a 1% revenue increase and a net loss, while also completing the divestiture of its medical writing business.

Certara, Inc. has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, aiming to sharpen its focus on Model-Informed Drug Development (MIDD).

Cynthia Collins will resign from Certara's Board of Directors and Audit Committee, effective May 14, 2026, citing no disagreements with the company.

Certara, a global leader in model-informed drug development, reported its fourth quarter and full fiscal year 2025 financial results, alongside its full year 2026 guidance.

Certara, a global leader in model-informed drug development, announced the appointment of Jon Resnick as its new Chief Executive Officer, effective January 1, 2026, succeeding Dr. William F. Feehery.

Certara, Inc. reported a 10% increase in third-quarter 2025 revenue to $104.6 million, driven by strong software growth, and updated its full-year 2025 financial guidance, raising profitability targets.

Certara, Inc. has entered into a Sixth Amendment to its credit agreement, expected to reduce its cost of borrowing and generate interest expense savings.

Certara, Inc. announced robust second quarter 2025 financial results, driven by significant growth in software revenue and a substantial reduction in net loss, while reiterating its full-year financial guidance.

Certara, Inc. held its annual meeting of stockholders on May 21, 2025, and the proposals outlined in the proxy statement were approved.

Certara announces a 10% increase in revenue for Q1 2025, driven by strong performance in biosimulation software and regulatory services.

Certara, Inc. announces a $100 million share repurchase authorization and preliminary Q1 2025 financial results, showing revenue growth and reiterating full-year guidance.

Dr. Patrick F. Smith stepped down as President of Certara Drug Development Solutions on March 3, 2025, and will transition to a senior advisory and scientific role within the company.

Certara, Inc. announced its Q4 2024 financial results, showcasing revenue growth and providing full-year 2025 financial guidance.

Certara reports preliminary fourth quarter and full year 2024 financial results, showing strong growth in revenue and bookings, and confirms adjusted EBITDA within the previously guided range.

Certara's third quarter results show an 11% revenue increase year-over-year, driven by strong growth in biosimulation software and services.

Certara Inc. has appointed Dr. John V. W. Reynders to its Board of Directors, effective immediately, increasing the board size to ten members.

Certara's second quarter results show strong software revenue growth of 13% but a 3% decline in services revenue, leading to a net loss of $12.6 million.

Certara Inc.'s Board of Directors approved amendments to the company's bylaws and restated its certificate of incorporation, primarily to remove provisions related to a former majority stockholder.

Certara, Inc. has announced a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software, to enhance its drug discovery capabilities.

Certara, Inc. has entered into a fifth amendment to its credit agreement, extending maturity dates and reducing borrowing costs.

Certara, Inc. held its annual shareholder meeting on May 21, 2024, where shareholders voted on the election of directors, amendments to the company's charter, ratification of the accounting firm, and executive compensation.

Certara's first quarter of 2024 saw a 7% revenue increase driven by strong software growth, but a net loss due to increased operating expenses.

Certara's Q4 2023 results show revenue growth but a net loss, with 2024 guidance projecting revenue growth and improved profitability.